Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
As of mid-2025, retatrutide is not approved for clinical use in the United Kingdom
Retatrutide (pronounced reh-TAT-tru-tide) is a synthetic peptide-based therapy that activates three key hormone receptors involved in metabolism: GLP-1 receptor (Glucagon-Like Peptide-1) GIP receptor (Glucose-Dependent Insulinotropic Polypeptide) Glucagon receptor This makes Retatrutide a triple agonist a unique advancement over medications like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) , which activate only one or two of these receptors
Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization
For perspective, the difference between the cheapest compounded tirzepatide provider ($219/month) and a mid-range provider ($400/month) over 12 months is $2,172
